{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-071014","form_type":"8-K/A","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.242681+00:00","generated_at":"2026-06-01T04:34:40.628098+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sagimet reports positive Phase 2b MASH data for denifanstat; primary endpoints met","bullets":["Primary endpoints achieved: ≥2-point NAS reduction without fibrosis worsening (38% vs 16%, p=0.0035) and MASH resolution (26% vs 11%, p=0.0173) in ITT.","Fibrosis improvement ≥1 stage without MASH worsening: ITT 30% vs 14% (p=0.0199); F3 subgroup 49% vs 13% (p=0.0032).","Fibrosis improvement ≥2 stages: mITT 20% vs 2% (p=0.0065); F3 34% vs 4% (p=0.0050).","No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo.","Company plans to initiate Phase 3 registrational program for denifanstat in MASH in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-071014","json":"https://secwatch.observer/filing/0001104659-24-071014.json","markdown":"https://secwatch.observer/filing/0001104659-24-071014.md","text":"https://secwatch.observer/filing/0001104659-24-071014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924071014/0001104659-24-071014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924071014/tm2417159d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:34:40.628098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}